

Daftar Pustaka

1. Bafina U, Priya S, Rajnesh KS, Satveer SG, Shuresh KB. Comparison of hypotensive properties of dexmedetomidine versus clonidine for induced hypotension during functional endoscopic sinus surgery: a randomised double-blind intervention study. *Indian J Anaesth.* 2021; 65:579-585
2. Fazel MR, Zeynab SA, Hossein A, and Fahimeh A. Effect of intraoperative dexmedetomidine infusion during functional endoscopic sinus surgery: a prospective cohort study. *BMC.* 2020;14(38):1-7
3. Gobind R. Controlled hypotensive anesthesia. Kwazulu: University of Kwazulu; 2011. 1-24
4. Bajwa BS. Induced Hypotensive anesthesia during elective surgical procedures. *J of Evolution of Med and Dnt Sci.* 2014;3(30):8418-26.
5. Upadhyay SP, Ulka S, Sudhakar ST, Sheriyar M, Partha PS, and Piyush NM. Controlled hypotension in modern anesthesia. *IJBR.* 2015;6(7):1043-58
6. Kundra S, Sachin T, Ashwani KC, Sunil K, Isha G, and Rajat R. Effect of a low dose dexmedetomidine infusion on intraoperative hemodynamics, anesthetic requirements and recovery profile in patients undergoing lumbar spine surgery. *J Anesth Clin Pharmacol.* 2019; 35(2):248-53
7. Butterworth JF, Edward M, and Maged SM. Intravenous anesthetics. In: David CM, John DW, editor. *Morgan & Mikhail's clinical anesthesiology.* 6th ed. New York: McGraw-Hill Education; 2018. pp 425-26.
8. Ubale, PV. Anesthetic considerations in functional endoscopic sinus surgery. *AIJOC.* 2015;7(1):22-7.
9. Enrico MA. Functional Endoscopic Sinus Surgery (FESS). Is It Always Safe Procedure? *OHNS.* 2019;4(5):pp1-5.
10. Daniel S, Nick J. *Manual of Endoscopy Sinus Surgery.* Stuttgart: George Thieme Verlag; 2005.
11. David EL, Sean CM. *Anesthesiology.* 3rd Edition. New York: McGraw-Hill Education; 2018.
12. Tim S. *Annual Queenstown Update In Anesthesia: ENT Update.* Auckland City: AQUA; 2014.
13. Jonas TJ, Clark A. *Bailey's Head and Neck Surgery Otolaryngology.* 5th edition. Philadelphia: Wolter Kluwer; 2014.
14. Amit S, Vladimir N. Anesthetic Considerations for Functional Endoscopic Sinus Surgery; Narrative Review. *JOHNA.* 2020; 4 (25); pp1-10.

15. Pei YT, Ruban P. Anaesthetic Concerns for Functional Endoscopic Sinus Surgery.. *Proced Singapore Healthcare*. 2014;23(3); pp 246-253.
16. Michel AG, Ronald DM, Neal HC. *Miller's Anesthesia*. 9 th edition. Philadelphia: Elsevier; 2020.
17. Lee S. Dexmedetomidine: present and future directions. *KJA*. 2019;72(4): 323-30.
18. Yazbek V and Aouad MM. Perioperative uses of dexmedetomidine. *MEJ Anesth*. 2006;18(6): 1043-58.
19. Robert KS, James PR, Pamela F, Steven Shafer. Vasodilator. In: Brian B, Nicole D, editor. *Stoelting's pharmacology and physiology in anesthetic practice*. 5 th ed. Philadelphia: Wolters Kluwe; 2015. pp 406-07
20. Barak M, Yoav L and Naaj IA. Hypotensive anesthesia versus normotensive anesthesia during maxillofacial surgery. *The Sci of J*. 2015;1:532-42.
21. Boisteanu O, Emilia P, Lidia C, Liviu VH, Carmen S, Emilia B, Daniela S, et al. Deliberate hypotension in anesthesia for major maxillofacial surgery. *I Rom J*. 2022;14 (4):67-71.
22. Tumulu R, et al., et al. Comparison between Sevoflurane and Isoflurane for Controlled Hypotensive Anesthesia in Patients Undergoing Craniotomy for Supratentorial Intracranial Surgery: A Randomised Single-Blinded Study. *Journal of Clinical and Diagnostic Research*. 2022; 16 (7): pp 27-30
23. Ankichetty S, Poniah M and Cherian V. Comparison of total intravenous Anesthesia using Propofol and Inhalational Anesthesia Using Isoflurane for Controlled Hypotension in Functional Endoscopic Sinus Surgery: *J Anaesth Clinical Pharmacol*. 2011; 27(3).
24. Tabrizi, R. Comparison of the effect of hypotensive anesthetic techniques on early recovery complications after orthognathic surgery. *J Craniofac Surg*. 2018; 23(3):1-5
25. Park SH, Do HS, Kim CS, Ro YJ, Han SH, Kim JH, et al. Controlling Deliberate Hypotension in Hypertensive Patients Undergoing Spinal Surgery: a Comparison Between Remifentanyl and Sodium Nitroprusside. *Anesth Pain Med*. 2010; 5(38): pp 38-44.
26. Zamani F, Naseri N, Farmani F and Kamali A. Comparison of the effect of dexmedetomidine and remifentanyl on controlled hypotension during rhinoplasty: A Clinical Trial Study. *International Tinnitus Journal*. 2020; 24 (2): pp 60-64.
27. Turgut N, Turkmen A, Gokkaya S, Altan A, and Hatiboglu MA. Dexmedetomidine-Base Versus Fentanyl- Base Total Intravenous Anesthesia for Lumbar Laminectomy. *Minerva Anaesth*. 2014;74(9):469-474.
28. Gupta KK, Vandana K, Sarvjet K, and Amanjot S. Comparative evaluation of propofol versus dexmedetomidine infusion for hypotensive anesthesia during functional endoscopic sinus surgery; a prospective randomized trial. *Anesth Pain Med*. 2021;17:271-79.

29. Seyrek M, Halici Z, Yildiz O, Ulusoy HB. Interaction between dexmedetomidine and α adrenergic receptors: Emphasis on vascular actions. *J Cardiothorac Vasc Anest* [Internet]. 2011;25(5):856–62. Tersedia pada: <http://dx.doi.org/10.1053/j.jvca.2011.06.006>
30. Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: From second- to first-line sedative agents in the critical care setting?. *J Intensive Care Med*. 2012;27(4):219–37.
31. Mohamed HS, Asida SM, and Salman OH. Dexmedetomidine versus nimodipin for controlled hypotension during spine surgery. *EGJA*.2019;23(4):325-31.
32. Shah A, Palmer AJR, Klein. Strategies to minimize intraoperative blood loss during major surgery. *BJS* .2020; 107: 26–38
33. Jin C, Xiang L, Yu S, and Hong J. Effect of continuous infusion of dexmedetomidine on blood loss in orthognathic surgery: a retrospective study. *Eur J Med Res*.2021;26(78):1-8
34. Mohamed HS, Salah MA, and Osama HS. Dexmedetomidine versus nimodipin for controlled hypotension during spine surgery. *EGJA*.2019;23(4):325-31.
35. Shah H, Kulkarni A. A comparative study between dexmedetomidine infusion and propofol infusion for maintenance in patients undergoing functional endoscopic sinus surgery under general anaesthesia. *IOSR JDMS* 2016; 15: 82-6.
36. Liu X, Li Y, Kang L, Wang Q. Recent advances in the clinical value and potential of dexmedetomidine. *J Inflamm Res* 2021;14:7507-26.
37. Kaur M, Singh P. Current role of dexmedetomidine in clinical anesthesia and intensive care. *Anesth Essays Res*. 2011;5(2):128.
38. Yuki K. Immunomodulatory mechanism of dexmedetomidine. *Int Immunopharmacol*. 2021;97(1):1-13
39. Weerink MA, Michel MRF, Laura NH, Clemens RM, Anthont RA. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. *Clin Pharmacokinet*. 2017;56:893-913
40. Gousheh SMR, Olapour AR, Nesioonpour S, Rashidi, and Pooyan S. The effect of intravenous infusion of dexmedetomidine to prevent bleeding during functional endoscopic sinus surgery. *Anesth Pain Med*. 2017; 7(4):1-5
41. Batra A, Verma R, Bhatia VK, Chandra G, Bhushan S. Dexmedetomidine as an Anesthetic Adjuvant in Intracranial Surgery. *Anesth Essays Res*. 2017 Apr-Jun;11(2):309-313.
42. Kim DH, Lee J, Kim SW, Hwang SH. The efficacy of hypotensive agents on intraoperative bleeding and recovery following general anesthesia for nasal surgery: A network meta-analysis. *Clin Exp Otorhinolaryngol* 2021;14:200-9.

43. Grape S, Kirkham KR, Frauenknecht J, Albrecht E. Intra-operative analgesia with remifentanyl vs. dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. *Anaesth.* 2019;74(16):793-800
44. Guo Q, Ma M, Yang Q, Yu H, Wang X, Wu C, et al. Effects of different sedatives/analgesics on stress responses in patients undergoing craniotomy and bone flap decompression. *J Int Med Res.* 2021;49(12):1-11

Lampiran 1 : Skala Fromme Boezart (Tingkatan Visualisasi Lapangan Pembedahan)

- Tingkat 0 = tidak ada perdarahan
- Tingkat 1 = perdarahan ringan, tidak membutuhkan suction
- Tingkat 2 = perdarahan ringan, sesekali membutuhkan suction. Visualisasi lapangan pembedahan tidak terancam.
- Tingkat 3 = perdarahan ringan; diperlukan penyedotan yang sering; perdarahan mengancam lapangan bedah beberapa detik setelah suction dilepaskan
- Tingkat 4: Pendarahan sedang; diperlukan penyedotan yang sering, perdarahan mengancam lapangan bedah langsung setelah suction dilepas
- Tingkat 5: perdarahan hebat: diperlukan suctioning terus-menerus, perdarahan muncul lebih cepat daripada yang dapat dihilangkan dengan suction, lapangan operasi sangat terancam dan pembedahan tidak mungkin dilakukan.

Sangat Baik (Kelas 0–1), Baik (Kelas 2–3), Kurang Baik (Kelas 4–5)

Lampiran 2 : Surat Etik Penelitian (1)



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JALAN PERintis KEMERDEKAAN KAMPUS TAMALAMBIA, KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Buhari, MPA,PhD,SpGA, TELP. 08214850858, 0411 5280103, Fax :0411-528431



REKOMENDASI PERSETUJUAN ETIK

Nomor : B70/UN4.6.4.5.31/PP36/2023

Tanggal: 14 Nopember 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23190764		No Sponsor	
Peneliti Utama	dr. Andi Epri Rangga Aditya Lisma		Sponsor	
Judul Peneliti	PENGARUH PEMBERIAN DOSIS RENDAH DEKSMEDETOMIDIN TERHADAP HIPOTENSI KENDAL INTRAPERATIF PADA FUNCTIONAL ENDOSCOPIC SINUS SURGERY (FESS)			
No Versi Protokol	2	Tanggal Versi	9 Nopember 2023	
No Versi PSP	2	Tanggal Versi	9 Nopember 2023	
Tempat Penelitian	RSUP Dr Wahidin Sudirohusodo Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 8 Nopember 2023		Masa Berlaku	Frekuensi review lanjutan
			14 Nopember 2023 sampai 14 Nopember 2024	
Ketua KEP Universitas Hasanuddin	Nama	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)		Tanda tangan
Sekretaris KEP Universitas Hasanuddin	Nama	dr. Firdaus Hamid, PhD, SpMK(K)		Tanda tangan

Kewajiban Peneliti Utama:

- Menyampaikan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyampaikan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyampaikan Laporan Kemajuan (progress report) setiap 6 bulan untuk penilaian risiko ulang dan setiap setahun untuk penilaian risiko rendah
- Menyampaikan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3: Hasil Output SPSS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
UMUR	.136	50	.021	.928	50	.005

a. Lilliefors Significance Correction

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
UMUR	50	30.66	7.591	17	43
KELOMPOK	50	.50	.505	0	1

Statistics

		UMUR_1	UMUR_0
N	Valid	25	25
	Missing	25	25
Median		28.00	35.00
Minimum		18	17
Maximum		43	40

Ranks

	KELOMPOK	N	Mean Rank	Sum of Ranks
UMUR	Kontrol	25	28.20	705.00
	Dexmed	25	22.80	570.00
	Total	50		

Test Statistics^a

	UMUR
Mann-Whitney U	245.000
Wilcoxon W	570.000
Z	-1.313
Asymp. Sig. (2-tailed)	.189

a. Grouping Variable: KELOMPOK

KELOMPOK * JENIS KELAMIN Crosstabulation

			JENIS KELAMIN		Total
			Laki-Laki	Perempuan	
KELOMPOK	Kontrol	Count	11	14	25
		% within KELOMPOK	44.0%	56.0%	100.0%
Dexmed	Dexmed	Count	11	14	25
		% within KELOMPOK	44.0%	56.0%	100.0%

Total	Count	22	28	50
	% within KELOMPOK	44.0%	56.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.000 ^a	1	1.000		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.000	1	1.000		
Fisher's Exact Test				1.000	.612
Linear-by-Linear Association	.000	1	1.000		
N of Valid Cases	50				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.00.

b. Computed only for a 2x2 table

PERDARAHAN

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
PERDARAHAN	.148	50	.008	.864	50	.000

a. Lilliefors Significance Correction

Statistics

		UMUR_1	UMUR_0
N	Valid	25	25
	Missing	25	25
Median		28.00	35.00
Minimum		18	17
Maximum		43	40

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
PERDARAHAN	50	148.00	110.841	10	600
KELOMPOK	50	.50	.505	0	1

Ranks

		KELOMPOK	N	Mean Rank	Sum of Ranks
PERDARAHAN	Kontrol		25	34.36	859.00
	Dexmed		25	16.64	416.00
	Total		50		

Test Statistics^a

		PERDARAHAN
Mann-Whitney U		91.000
Wilcoxon W		416.000
Z		-4.337
Asymp. Sig. (2-tailed)		.000

a. Grouping Variable: KELOMPOK

AGEN ANESTESI

KELOMPOK * AGEN_ANESTESI Crosstabulation

			AGEN ANESTESI		Total
			Tidak	Ya	
KELOMPOK	Dexmed	Count	23	2	25
		% within KELOMPOK	92.0%	8.0%	100.0%
	Kontrol	Count	6	19	25
		% within KELOMPOK	24.0%	76.0%	100.0%
Total		Count	29	21	50
		% within KELOMPOK	58.0%	42.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	23.727 ^a	1	.000		
Continuity Correction ^b	21.018	1	.000		
Likelihood Ratio	26.537	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	23.253	1	.000		
N of Valid Cases	50				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 10.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for KELOMPOK (Dexmed / Kontrol)	36.417	6.575	201.704
For cohort AGEN_ANESTESI = Tidak	3.833	1.890	7.774
For cohort AGEN_ANESTESI = Ya	.105	.027	.405
N of Valid Cases	50		

WAKTU PULIH SADAR

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
EMERGENCE_TIME	.204	50	.000	.878	50	.000
EKSTUB_TIME	.230	50	.000	.894	50	.000

a. Lilliefors Significance Correction

Statistics

		EM 1	EM 0	EX 1	EX 0
N	Valid	25	25	25	25
	Missing	25	25	25	25
Median		4.00	10.00	6.00	12.00
Minimum		2	6	4	9
Maximum		8	12	12	15

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
EMERGENCE_TIME	50	6.84	3.119	2	12
EKSTUB_TIME	50	9.14	3.251	4	15
KELOMPOK	50	.50	.505	0	1

Ranks

	KELOMPOK	N	Mean Rank	Sum of Ranks
EMERGENCE_TIME	Dexmed	25	13.16	329.00
	Kontrol	25	37.84	946.00
	Total	50		
EKSTUB_TIME	Dexmed	25	13.48	337.00
	Kontrol	25	37.52	938.00
	Total	50		

Test Statistics^a

	EMERGENCE_ TIME	EKSTUB TIME
Mann-Whitney U	4.000	12.000
Wilcoxon W	329.000	337.000
Z	-6.083	-5.919
Asymp. Sig. (2-tailed)	.000	.000

a. Grouping Variable: KELOMPOK

NRS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
NRS_PB	.436	50	.000	.603	50	.000

a. Lilliefors Significance Correction

Statistics

		NRS 1	NRS 0
N	Valid	25	25
	Missing	25	25
Median		1.00	2.00
Minimum		1	1
Maximum		1	3

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
NRS_PB	50	1.38	.667	1	3
KELOMPOK	50	.50	.505	0	1

Ranks

		KELOMPOK	N	Mean Rank	Sum of Ranks
NRS_PB	Dexmed		25	18.50	462.50
	Kontrol		25	32.50	812.50
	Total		50		

Test Statistics^a

	NRS_PB
Mann-Whitney U	137.500
Wilcoxon W	462.500
Z	-4.312
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: KELOMPOK

LAPANGAN OPERASI

Kelompok Deksmetomidine

Statistics

LAPANGAN_OP

N	Valid	25
	Missing	25
Median		2.00
Minimum		1
Maximum		2

LAPANGAN_OP

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	1	4	8.0	16.0	16.0
	2	21	42.0	84.0	100.0
	Total	25	50.0	100.0	
Missing	System	25	50.0		
Total		50	100.0		

Kelompok Kontrol

Statistics

LAPANGAN_OP

N	Valid	25
	Missing	25
Median		4.00
Minimum		3
Maximum		4

LAPANGAN_OP

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	3	8	16.0	32.0	32.0
	4	17	34.0	68.0	100.0
	Total	25	50.0	100.0	
Missing	System	25	50.0		
Total		50	100.0		

Ranks

	KELOMPOK	N	Mean Rank	Sum of Ranks
LAPANGAN_OP	Kontrol	25	38.00	950.00
	Dexmed	25	13.00	325.00
	Total	50		

Test Statistics^a

	LAPANGAN_O P
Mann-Whitney U	.000
Wilcoxon W	325.000
Z	-6.455
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: KELOMPOK

HIPOTENSI KENDALI

TEKANAN DARAH SISTOLIK

Test Statistics^a

	TDS 0	TDS SBI	TDS SDI	TDS SDT	TDS INSISI	TDS 15	TDS 30	TDS 45	TDS 60	TDS 75	TDS 90	TDS 105	TDS 120
Mann-Whitney U	172.500	199.500	190.000	227.000	189.000	156.000	138.500	77.000	89.000	42.000	20.500	11.000	5.500
Wilcoxon W	497.500	524.500	515.000	552.000	514.000	481.000	463.500	402.000	389.000	178.000	140.500	89.000	50.500
Z	-2.729	-2.195	-2.381	-1.661	-2.403	-3.041	-3.385	-4.467	-4.107	-3.391	-3.936	-3.241	-1.937
Asymp. Sig. (2-tailed)	.006	.028	.017	.097	.016	.002	.001	.000	.000	.001	.000	.001	.053
Exact Sig. [2*(1-tailed Sig.)]										.000 ^b	.000 ^b	.001 ^b	.050 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

TEKANAN DARAH DIASTOLIK

Test Statistics^a

	TDD 0	TDD SBI	TDD SDI	TDD SDT	TDD INSISI	TDD 15	TDD 30	TDD 45	TDD 60	TDD 75	TDD 90	TDD 105	TDD 120
Mann-Whitney U	198.500	238.500	260.500	251.500	270.000	227.500	167.500	77.500	128.000	38.500	62.500	37.000	10.500
Wilcoxon W	523.500	563.500	585.500	576.500	595.000	552.500	492.500	402.500	428.000	174.500	182.500	115.000	55.500
Z	-2.217	-1.437	-1.010	-1.185	-.826	-1.651	-2.822	-4.455	-3.308	-3.518	-2.279	-1.526	-1.162
Asymp. Sig. (2-tailed)	.027	.151	.312	.236	.409	.099	.005	.000	.001	.000	.023	.127	.245
Exact Sig. [2*(1-tailed Sig.)]										.000 ^b	.021 ^b	.140 ^b	.260 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

TEKANAN ARTERI RERATA

Test Statistics^a

	TAR 0	TAR SBI	TAR SDI	TAR SDT	TAR INSISI	TAR 15	TAR 30	TAR 45	TAR 60	TAR 75	TAR 90	TAR 105	TAR 120
Mann-Whitney U U//////////	197.000	224.000	209.500	252.000	282.000	230.000	154.500	87.000	101.000	50.000	68.500	22.000	11.000
Wilcoxon W	522.000	549.000	534.500	577.000	607.000	555.000	479.500	387.000	377.000	186.000	188.500	100.000	66.000
Z	-2.243	-1.720	-2.001	-1.176	-.593	-1.604	-3.071	-4.264	-3.854	-3.104	-2.038	-2.515	-1.278
Asymp. Sig. (2-tailed)	.025	.085	.045	.240	.553	.109	.002	.000	.000	.002	.042	.012	.201
Exact Sig. [2*(1-tailed Sig.)]										.001 ^b	.041 ^b	.011 ^b	.240 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

LAJU NADI

Test Statistics^a

	HR 0	HR SBI	HR SDI	HR SDT	HR INSISI	HR 15	HR 30	HR 45	HR 60	HR 75	HR 90	HR 105	HR 120
Mann-Whitney U	248.000	213.000	213.000	178.500	176.000	162.000	129.500	154.500	126.000	65.500	98.500	55.000	15.000
Wilcoxon W	573.000	538.000	538.000	503.500	501.000	487.000	454.500	479.500	426.000	201.500	234.500	133.000	70.000
Z	-1.254	-1.934	-1.934	-2.603	-2.651	-2.927	-3.555	-3.069	-3.485	-2.542	-1.113	-.330	-.708
Asymp. Sig. (2-tailed)	.210	.053	.053	.009	.008	.003	.000	.002	.000	.011	.266	.741	.479
Exact Sig. [2*(1-tailed Sig.)]										.010 ^b	.270 ^b	.771 ^b	.539 ^b

a. Grouping Variable: KELOMPOK

b. Not corrected for ties.

BIS

Statistics

		BIS 0	BIS SBI	BIS SDI	BIS SDT	BIS INSISI	BIS 15	BIS 30	BIS 45	BIS 60	BIS 75	BIS 90	BIS 105	BIS 120
N	Valid	25	25	25	25	25	25	25	25	24	16	15	14	10
	Missing	25	25	25	25	25	25	25	25	26	34	35	36	40
Median		98.00	88.00	48.00	47.00	45.00	45.00	46.00	47.00	48.00	48.00	47.00	47.00	49.00
Minimum		94	85	38	41	41	39	40	40	42	42	41	43	42
Maximum		99	94	68	61	56	60	56	55	56	51	58	53	53

Statistics

		BIS 0	BIS SBI	BIS SDI	BIS SDT	BIS INSISI	BIS 15	BIS 30	BIS 45	BIS 60	BIS 75	BIS 90	BIS 105	BIS 120
N	Valid	25	25	25	25	25	25	25	25	25	17	16	10	4
	Missing	25	25	25	25	25	25	25	25	25	33	34	40	46
Median		98.00	89.00	48.00	48.00	46.00	45.00	46.00	45.00	48.00	48.00	48.50	50.50	50.00
Minimum		97	85	40	41	35	41	40	41	41	37	42	45	48
Maximum		99	92	55	53	55	49	56	61	65	63	54	59	51

Test Statistics^a

	BIS 0	BIS SBI	BIS SDI	BIS SDT	BIS INSISI	BIS 15	BIS 30	BIS 45	BIS 60	BIS 75	BIS 90	BIS 105	BIS 120
Mann-Whitney U	219.500	283.000	309.000	280.500	241.000	249.000	306.000	308.500	297.000	125.500	98.000	48.500	20.000
Wilcoxon W	544.500	608.000	634.000	605.500	566.000	574.000	631.000	633.500	597.000	261.500	218.000	153.500	75.000
Z	-2.294	-.583	-.069	-.625	-1.406	-1.242	-.127	-.078	-.060	-.383	-.877	-1.267	.000
Asymp. Sig. (2-tailed)	.022	.560	.945	.532	.160	.214	.899	.938	.952	.702	.380	.205	1.000
Exact Sig. [2*(1-tailed Sig.)]										.709 ^b	.401 ^b	.212 ^b	1.000 ^b

a. Grouping Variable: KELOMPOK
Not corrected for ties

